Clinical Study

Nrg-Lu007- The Raptor Trial (Nrg-Lu007) For Extensive Stage Small Cell Lung Cancer; Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy For Es-Sclc

Posted Date: Sep 28, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Radiation Oncology
  • Type of Study: Device

This trial will be testing if adding radiation to the immunotherapy drug atezolizumab for patients with extensive stage small cell lung cancer (ES-SCLC) can improve progression-free survival (phase II) and overall survival (phase III) when compared to atezolizumab alone.

Criteria:

Patients With Extensive Stage Small Cell Lung Cancer Who Have Recieved 4-6 Cycles Of Etoposide/Platinum Chemotherapy + Atezolizumab Who Have A Stable Or Or Partial Response

Keywords:

Extensive Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Immunotherapy

For More Information:

Emily Daugherty, Md
513-584-4073
daugheec@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.